Efficacy of Oral 20-Hydroxyecdysone (BIO101), a MAS Receptor Activator, in Adults with Severe COVID-19 (COVA): a Randomized, Placebo-Controlled, Phase 2/3 Trial Suzana Margareth Lobo , Gaetan Plantefeve , Girish Nair , Adilson Joaquim Cavalcante , Nara Franzin de Moraes , Estevao Nunes , Otis Barnum , Claudio Marcel Berdun Stadnik , Maria Patelli Lima , Muriel Lins , Ludhmila Abrahao Hajjar , Christopher Lipinski , Shaheen Islam , Fabiano Ramos , Tiago Simon , Jean-Benoit Martinoti , Thomas Guimard , Arnaud Desclaux , Bertrand Lioger , Fernando Carvalho Neuenschwander , Bruno DeSouza Paolino , Alpesh Amin , Samuel Amil Acosta , Daniel Forde Dilling , Edgardo Cartagena , Brian Snyder , Edouard Devaud , Ana Karolina Barreto Berselli Marinho , Suzana Tanni , Patricia Medeiros Milhomem Beato , Stephan Dewit , Vani Selvan , Jeffrey Gray , Ricardo Fernandez , Valerie Pourcher , Lee Maddox , Richard Kay , Anait Azbekyan , Mounia Chabane , Cendrine Tourette , Luis Everton Esmeraldino , Pierre J. Dilda , Rene Lafont , Jean Mariani , Serge Camelo , Sandrine Rabut , Samuel Agus , Stanislas Veillet , Waly Dioh , Rob van Maanen , Capucine Morelot-Panzini ECLINICALMEDICINE（2024）
关键词
SARS-CoV-2, COVID-19, Renin-angiotensin-system (RAS), MasR, 20-Hydroxyecdysone, Respiratory failure
AI 理解论文
溯源树
样例
